NRD
TERN

Nebula Research & Development’s Terns Pharmaceuticals TERN Stock Holding History

Nebula Research & Development’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,637
Closed -$34.9K – 1152
2025
Q1 		$34.9K Sell
12,637
-13,212
-51% -$54K ﹤0.01% 924
2024
Q4 		$143K Buy
25,849
+14,521
+128% +$98.3K 0.02% 839
2024
Q3 		$94.5K Buy
+11,328
New +$93.2K 0.01% 880

Other funds holding TERN

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Nebula Research & Development's TERN Position: Q2 2025 in Review

Nebula Research & Development sold out of Terns Pharmaceuticals (TERN) in Q2 2025, closing a stake of 12,637 shares — an estimated $34.9K sold.

Nebula Research & Development first reported a position in TERN in Q3 2024 and held it in 3 quarters. The position peaked at $143K in Q4 2024. 129 funds tracked by Wall St. Rank hold TERN as of Q2 2025.

  • Nebula Research & Development reported no remaining Terns Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Nebula Research & Development sold 12,637 Terns Pharmaceuticals shares in Q2 2025, an estimated $34.9K.
  • Nebula Research & Development first reported a position in Terns Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Nebula Research & Development's Terns Pharmaceuticals position peaked at $143K in Q4 2024.
  • 129 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2025.

Based on Nebula Research & Development's 13F filing for Q2 2025, filed 14 Aug 2025.